Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Opyrchal M, Gil M, Salisbury JL, Goetz MP, Suman V, Degnim A, McCubrey J, Haddad T, Iankov I, Kurokawa CB, Shumacher N, Ingle JN, Galanis E, D'Assoro AB.

Oncotarget. 2017 Sep 1;8(53):91803-91816. doi: 10.18632/oncotarget.20610. eCollection 2017 Oct 31.

2.

Remote sensing measurements of sea surface temperature as an indicator of Vibrio parahaemolyticus in oyster meat and human illnesses.

Konrad S, Paduraru P, Romero-Barrios P, Henderson SB, Galanis E.

Environ Health. 2017 Aug 31;16(1):92. doi: 10.1186/s12940-017-0301-x.

3.

Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma.

Domingo-Musibay E, Heun JM, Nevala WK, Callstrom M, Atwell T, Galanis E, Erickson LA, Markovic SN.

Oncologist. 2017 Sep;22(9):1026-e93. doi: 10.1634/theoncologist.2017-0060. Epub 2017 Jul 5.

4.

Evaluating the Timeliness of Enteric Disease Surveillance in British Columbia, Canada, 2012-13.

Galanis E, Taylor M, Romanowski K, Bitzikos O, Jeyes J, Nowakowski C, Stone J, Murti M, Paccagnella A, Forsting S, Li S, Hoang L.

Can J Infect Dis Med Microbiol. 2017;2017:9854103. doi: 10.1155/2017/9854103. Epub 2017 Jun 1.

5.

Where size matters: imaging-based biomarkers for patient stratification.

Erickson BJ, Galanis E.

Neuro Oncol. 2017 Jan;19(1):7-8. doi: 10.1093/neuonc/now248. No abstract available.

6.

Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.

Kurokawa C, Geekiyanage H, Allen C, Iankov I, Schroeder M, Carlson B, Bakken K, Sarkaria J, Ecsedy JA, D'Assoro A, Friday B, Galanis E.

J Neurooncol. 2017 Jan;131(1):41-48. doi: 10.1007/s11060-016-2285-8. Epub 2016 Nov 5.

7.

MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors.

Geekiyanage H, Galanis E.

Mol Oncol. 2016 Nov;10(9):1387-1403. doi: 10.1016/j.molonc.2016.07.007. Epub 2016 Jul 28.

8.

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL.

JAMA. 2016 Jul 26;316(4):401-9. doi: 10.1001/jama.2016.9839.

9.

Aurora-A Kinase as a Promising Therapeutic Target in Cancer.

D'Assoro AB, Haddad T, Galanis E.

Front Oncol. 2016 Jan 6;5:295. doi: 10.3389/fonc.2015.00295. eCollection 2015. Review.

10.

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).

Brown PD, Anderson SK, Carrero XW, O'Neill BP, Giannini C, Galanis E, Shah SA, Abrams RA, Curran WJ Jr, Buckner JC, Shaw EG.

Neurooncol Pract. 2015 Dec;2(4):199-204. Epub 2015 Aug 6.

11.

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.

Baldo A, Galanis E, Tangy F, Herman P.

Hum Vaccin Immunother. 2016 May 3;12(5):1102-16. doi: 10.1080/21645515.2015.1122146. Epub 2015 Dec 2. Review.

12.

What next for newly diagnosed glioblastoma?

Domingo-Musibay E, Galanis E.

Future Oncol. 2015;11(24):3273-83. doi: 10.2217/fon.15.258. Epub 2015 Nov 12. Review.

13.

Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.

Iankov ID, Kurokawa CB, D'Assoro AB, Ingle JN, Domingo-Musibay E, Allen C, Crosby CM, Nair AA, Liu MC, Aderca I, Federspiel MJ, Galanis E.

Cancer Gene Ther. 2015 Sep;22(9):438-44. doi: 10.1038/cgt.2015.36. Epub 2015 Aug 14.

14.

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee.

Neuro Oncol. 2015 Sep;17(9):1188-98. doi: 10.1093/neuonc/nov095. Epub 2015 Aug 5. Review.

15.

Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.

Berg AK, Buckner JC, Galanis E, Jaeckle KA, Ames MM, Reid JM.

J Clin Pharmacol. 2015 Nov;55(11):1303-12. doi: 10.1002/jcph.543. Epub 2015 Jun 26.

16.

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN.

Neuro Oncol. 2015 Sep;17(9):1261-9. doi: 10.1093/neuonc/nou328. Epub 2014 Dec 18.

17.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC.

Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14.

18.

Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma.

Domingo-Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E.

Cancer Gene Ther. 2014 Nov;21(11):483-90. doi: 10.1038/cgt.2014.54. Epub 2014 Nov 14.

19.

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY.

Neuro Oncol. 2015 Feb;17(2):180-8. doi: 10.1093/neuonc/nou154. Epub 2014 Aug 26. Review.

20.

Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.

Opyrchal M, Salisbury JL, Iankov I, Goetz MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis E, D'Assoro AB.

Int J Oncol. 2014 Sep;45(3):1193-9. doi: 10.3892/ijo.2014.2523. Epub 2014 Jun 25.

Supplemental Content

Loading ...
Support Center